ProCE Banner Activity

A New Nivolumab Dosing Option for Our Patients With Advanced NSCLC

Clinical Thought
How will the new dosing schedule for nivolumab in NSCLC affect our current practice? Here are my thoughts.

Released: April 16, 2018

Share

Faculty

Edward B Garon

Edward B Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Faculty Disclosure

Primary Author

Edward B Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has disclosed that he has received funds for research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dynavax, Genentech, Eli Lilly, Merck, Mirati, Novartis, and Pfizer.